Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents

Clinica Chimica Acta

Volumn 314, Issue 1-2, 2001, Pages 159-166

  Kestell, Philip ^a   Zhao, Liangli ^a   Jameson, Michael B ^a   Stratford, Michael R L ^b   Folkes, Lisa K ^b   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

High performance liquid chromatography; Platelets; Serotonin

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; ATENOLOL; CETRIMIDE; CIMETIDINE; CODEINE; CYCLIZINE; DEXTROPROPOXYPHENE; DICLOFENAC; DRUG METABOLITE; FUROSEMIDE; IBUPROFEN; LAXATIVE; LOPERAMIDE; LORAZEPAM; METOCLOPRAMIDE; MORPHINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; ONDANSETRON; PARACETAMOL; PROPRANOLOL; SALBUTAMOL; SENNA EXTRACT; SEROTONIN; TEMAZEPAM; UNINDEXED DRUG; ZOPICLONE; 5,6 DIMETHYLXANTHENONEACETIC ACID; 5,6-DIMETHYLXANTHENONEACETIC ACID; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; XANTHENE DERIVATIVE;

ACCURACY; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; DIET; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG STABILITY; ELECTROCHEMICAL DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEROTONIN RELEASE; SOLID PHASE EXTRACTION; BLOOD; BLOOD FLOW; CALIBRATION; DRUG EFFECT; ELECTROCHEMISTRY; NEOPLASM; QUALITY CONTROL; REPRODUCIBILITY; SOLUTION AND SOLUBILITY; STANDARD; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; BIOLOGICAL MARKERS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS, PHASE I; ELECTROCHEMISTRY; HUMAN; HYDROXYINDOLEACETIC ACID; NEOPLASMS; QUALITY CONTROL; REFERENCE STANDARDS; REGIONAL BLOOD FLOW; REPRODUCIBILITY OF RESULTS; SOLUTIONS; SUPPORT, NON-U.S. GOV'T; XANTHENES;

EID: 0035164766     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(01)00692-1     Document Type: Article

References (25)

1. Changes in serotonin metabolism in cancer patients - Its relationship to nausea and vomiting induced by chemotherapeutic drugs
2. Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: Comparative effects of granisetron and ondansetron
3. High performance liquid chromatographic profiling of tryptophan and related indoles in body fluids and tissues of carcinoid patients
4. Simultaneous analysis of homovanillic acid, 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenylethylene glycol and vanilmandelic acid in plasma from alcoholics by high-performance liquid chromatography with electrochemical detection: Critical comparison of solid-phase and liquid-liquid extraction methods
5. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine - Relation to vascular effects
6. Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy
7. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine - Evidence for a vascular mechanism
8. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents
9. Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
10. Phase I pharmacokinetic and toxicity study of weekly intravenous combretastatin A4 phosphate (CA4P)
11. Impact on tumour perfusion measured by dynamic magnetic resonance imaging (MRI), in the phase 1 trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
12. Scintigraphic imaging of the hypoxia marker (99m)Technetium-labeled 2,2′-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (Tc-99m-labeled HL-91; Prognox): Noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid
13. Determination of tryptophan and its metabolites in human plasma and serum by high-performance liquid chromatography with automated sample clean-up system
14. On the accurate determination of serotonin in human plasma
15. Determination of serotonin in plasma by liquid chromatography with electrochemical detection
16. Determination of 5-hydroxytrytamine and 5-hydroxyindolacetic acid in plasma by direct injection in coupled-column liquid chromatography with electrochemical detection
17. Determination of plasma serotonin and 5-hydroxyindoleacetic acid in healthy subjects and cancer patients
18. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
19. Rapid and simple method for the simultaneous determination of 3,4-dihydroxyphenylacetic acid, 5-hydroxyindole-3-acetic acid, 4-hydroxy-3-methoxyphenylacetic acid in human plasma by high-performance liquid chromatography with electrochemical detection
20. Determination of 3,4-dihydroxyphenylacetic acid and 5-hydroxyindole acetic acid in human plasma by a simple and rapid high-performance liquid chromatography assay
21. Determination of plasma 5-hyrdroxytryptophan, 5-hydroxytryptamine, 5-hydroxyindoleacetic acid, tryptophan and melatonin by high-performance liquid chromatography with electrochemical detection
22. Rapid and reliable high-performance liquid chromatographic method for analysing human plasma serotonin, 5-hydroxyindoleacetic acid, homovanillic acid and 3,4-dihydroxyphenylacetic acid
23. Assay detection limits: Concept, definition, and estimation
24. Analytical methods validation: Bioavailability, bioequivalence and pharmacological studies
25. Simultaneous determination of the major acidic metabolites of catecholamines and serotonin in urine by liquid chromatography with electrochemical detection after a one-step sample clean-up on Sephadex G-10; influence of vanilla and banana ingestion